Table 1. Patient and Tumor Characteristics at Baseline.
| Variable | No. (%) | |
|---|---|---|
| Capecitabine group (n = 221) | Observation group (n = 213) | |
| Age, y | ||
| ≤40 | 62 (28.1) | 49 (23.0) |
| 41-50 | 85 (38.5) | 72 (33.8) |
| ≥51 | 74 (33.5) | 92 (43.2) |
| Median, IQR | 45 (39-53) | 48 (40-57) |
| Premenopausal | 157 (71.0) | 133 (62.4) |
| Tumor size, cma | ||
| ≤2 | 79 (35.7) | 79 (37.1) |
| >2 to ≤5 | 122 (55.2) | 124 (58.2) |
| >5 | 20 (9.1) | 10 (4.7) |
| Node status | ||
| Negative | 135 (61.1) | 133 (62.4) |
| 1-3 positive nodes | 46 (20.8) | 41 (19.2) |
| 4-9 positive nodes | 14 (6.3) | 25 (11.7) |
| ≥10 positive nodes | 26 (11.8) | 14 (6.6) |
| Stage at diagnosis (AJCC 2010)b | ||
| I | 56 (25.3) | 59 (27.7) |
| II | 120 (54.3) | 116 (54.5) |
| III | 45 (20.4) | 38 (17.8) |
| Histological gradec | ||
| 1 | 5 (2.3) | 3 (1.4) |
| 2 | 52 (23.5) | 58 (27.2) |
| 3 | 164 (74.2) | 152 (71.4) |
| Ki-67 index at diagnosis <30%d | 44 (19.9) | 57 (26.8) |
| Lymphovascular invasion | 42 (19.0) | 23 (10.8) |
| Type of surgery | ||
| Mastectomy | 186 (84.2) | 189 (88.7) |
| Lumpectomy | 35 (15.8) | 24 (11.3) |
| Lymph node dissection | ||
| Axillary-node dissection | 176 (79.6) | 169 (79.3) |
| Sentinel-node biopsy only | 45 (20.4) | 44 (20.7) |
| Chemotherapy received | ||
| Adjuvant only | 209 (94.5) | 195 (91.5) |
| Neoadjuvant only | 7 (3.2) | 11 (5.2) |
| Adjuvant and neoadjuvant | 5 (2.3) | 7 (3.3) |
| Chemotherapy regimen | ||
| Anthracyclines and taxane | 198 (89.6) | 189 (88.7) |
| Taxane only | 20 (9.0) | 21 (9.9) |
| Anthracyclines only | 3 (1.4) | 3 (1.4) |
| Received radiotherapy | 111 (50.2) | 86 (40.6) |
Abbreviations: AJCC, American Joint Committee on Cancer; IQR, interquartile range.
a
Tumor size at diagnosis was based on pathological assessment.
b
Stage at diagnosis was based on AJCC 2010, seventh edition.
c
Histological grade at diagnosis was based on the degree of the tumor’s histologic differentiation.
d
Ki-67 index at diagnosis indicates DNA synthetic activity as measured by immunocytochemistry.